# Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

Source: https://onco.cc/trials/nct06619236/  
OnCo record `nct06619236` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Rinatabart sesutecan, Paclitaxel / nab-paclitaxel, Topotecan in ovarian cancer, run by Genmab, active and no longer recruiting.

## Summary

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer is a phase 3 interventional study registered as NCT06619236 by Genmab, with 530 participants planned, started 2025-02-07 and due to reach its primary completion in 2027-02. Interventions recorded: Rina-S, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin (PLD), Gemcitabine. Conditions listed: Platinum-resistant Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06619236
- Phase: 3
- Setting: A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer
- Sponsor: Genmab
- Enrolled: 530

## Sources

- ClinicalTrials.gov NCT06619236: https://clinicaltrials.gov/study/NCT06619236

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pegylated liposomal doxorubicin](https://onco.cc/drugs/pegylated-liposomal-doxorubicin/), [Rinatabart sesutecan](https://onco.cc/drugs/rinatabart-sesutecan/), [Topotecan](https://onco.cc/drugs/topotecan/)
- companies: [Genmab](https://onco.cc/companies/genmab/)

---
JSON: https://onco.cc/api/v1/entities/nct06619236.json